

(Print or Type Responses)

1. Name and Address of Reporting Person* NEIS JOHN		2. Issuer Name and Ticker or Trading Symbol Collectar Biosciences, Inc. [CLRB]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) ☒ Director ☐ Officer (give title below) ☐ 10% Owner ☐ Other (specify below)			
(Last) (First) (Middle) C/O COLLECTAR BIOSCIENCES, INC., 100 CAMPUS DRIVE		3. Date of Earliest Transaction (Month/Day/Year) 03/12/2021					
(Street) FLORHAM PARK, NJ 07932		4. If Amendment, Date Original Filed(Month/Day/Year)		6. Individual or Joint/Group Filing(Check Applicable Line) ☒ Form filed by One Reporting Person ☐ Form filed by More than One Reporting Person			
(City) (State) (Zip)		Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A Warrants	\$ 30.4	03/12/2021		S		41,155	04/20/2016	04/20/2021	Common Stock	4,115 (1)	\$ 0.2668	193,587	D	
Series A Warrants	\$ 30.4	03/15/2021		S		11,200	04/20/2016	04/20/2021	Common Stock	1,120 (2)	\$ 0.2652	182,387	D	
Series A Warrants	\$ 30.4	03/16/2021		S		100,515	04/20/2016	04/20/2021	Common Stock	10,051 (3)	\$ 0.3091	81,872	D	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
NEIS JOHN C/O COLLECTAR BIOSCIENCES, INC. 100 CAMPUS DRIVE FLORHAM PARK, NJ 07932	X			

Signatures

/s/ Christina Blakley, attorney-in-fact for John Neis		03/16/2021
**Signature of Reporting Person		Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The price reported is a weighted average price. These warrants were sold in multiple transactions at prices ranging from \$0.2648 and \$0.27, inclusive. The reporting person undertakes to
(1) provide the staff of the Securities and Exchange Commission, upon request, full information regarding the number of warrants sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

The price reported is a weighted average price. These warrants were sold in multiple transactions at prices ranging from \$0.265 and \$0.2666, inclusive. The reporting person undertakes to
(2) provide the staff of the Securities and Exchange Commission, upon request, full information regarding the number of warrants sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

The price reported is a weighted average price. These warrants were sold in multiple transactions at prices ranging from \$0.28 and \$0.34, inclusive. The reporting person undertakes to provide
(3) the staff of the Securities and Exchange Commission, upon request, full information regarding the number of warrants sold at each separate price within the ranges set forth in footnote (3) to this Form 4.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.